In cases, when sorafenib was used as treatment of relapsed or refractory AML, a fast and efficient leukoreduction has been reported (20–22), suggesting that it might be of clinical benefit in the management of hyperleukocytosis, even in cases where the FLT3-ITD status in unknown. The gene discussed is FLT3; the disease is acute myeloid leukemia.